Oral Healthcare Company C3 Jian Bites Off $60.5M Series D
March 20, 2014
C3 Jian, a company developing drugs to improve oral healthcare, has closed a $60.5 million Series D financing round led by Renaissance Holding Company. Funds from the financing will be used to support continued clinical development of the company’s lead product, C16G2, a peptide-based antimicrobial drug specifically targeting Streptococcus mutans, a bacterium responsible for dental caries or tooth decay. Under a U.S. FDA Investigational New Drug Application, C3 Jian recently began a Phase 2 Clinical Trial to study C16G2 formulated as a mouth rinse as well as a gel for both dental tray and toothbrush applications. Proceeds received will also help advance development of a second peptide drug candidate that has both teeth remineralization and hair/nail growth properties. With the new investment, C3 Jian has now raised about $113 million of funding to date.